Last reviewed · How we verify
Propranolol LA
Propranolol LA is a Non-selective beta-adrenergic antagonist Small molecule drug developed by MetroHealth Medical Center. It is currently in Phase 3 development for Hypertension, Angina pectoris, Cardiac arrhythmias. Also known as: Inderal LA.
Propranolol is a non-selective beta-adrenergic receptor antagonist that blocks the effects of epinephrine and norepinephrine on the heart and blood vessels.
Propranolol LA is a small molecule that acts as a beta-1 adrenergic receptor antagonist. It has been studied in clinical trials for various conditions, including labor, postural tachycardia syndrome, and shoulder pain.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Propranolol LA |
|---|---|
| Also known as | Inderal LA |
| Sponsor | MetroHealth Medical Center |
| Drug class | Non-selective beta-adrenergic antagonist |
| Target | Beta-1 and beta-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Propranolol competitively inhibits beta-1 and beta-2 adrenergic receptors, reducing heart rate, cardiac contractility, and blood pressure. The long-acting (LA) formulation provides sustained drug release over 24 hours, allowing once-daily dosing. This mechanism makes it effective for managing hypertension, angina, arrhythmias, and other cardiovascular conditions.
Approved indications
- Hypertension
- Angina pectoris
- Cardiac arrhythmias
- Myocardial infarction secondary prevention
- Essential tremor
- Migraine prophylaxis
Common side effects
- Fatigue
- Dizziness
- Bradycardia
- Hypotension
- Bronchospasm
- Sexual dysfunction
- Insomnia
Key clinical trials
- Modafinil and Cognitive Function in POTS (EARLY_PHASE1)
- Propranolol for Sleep Apnea Therapy (PHASE2)
- Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg (PHASE1)
- Food Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg (PHASE1)
- Biopsychosocial Influence on Shoulder Pain (PHASE2)
- Propranolol for Protracted Labor (PHASE1)
- Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy (PHASE2)
- Perioperative Propranolol in Patients With Post Traumatic Stress Disorder (PTSD) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Propranolol LA CI brief — competitive landscape report
- Propranolol LA updates RSS · CI watch RSS
- MetroHealth Medical Center portfolio CI
Frequently asked questions about Propranolol LA
What is Propranolol LA?
How does Propranolol LA work?
What is Propranolol LA used for?
Who makes Propranolol LA?
Is Propranolol LA also known as anything else?
What drug class is Propranolol LA in?
What development phase is Propranolol LA in?
What are the side effects of Propranolol LA?
What does Propranolol LA target?
Related
- Drug class: All Non-selective beta-adrenergic antagonist drugs
- Target: All drugs targeting Beta-1 and beta-2 adrenergic receptors
- Manufacturer: MetroHealth Medical Center — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Angina pectoris
- Indication: Drugs for Cardiac arrhythmias
- Also known as: Inderal LA
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing